This article is more than 5 years old. Information may no longer be current.
ThromboGenics changes name to Oxurion
ThromboGenics announced its shareholders approved a new name for the company, Oxurion, at an extraordinary general meeting.
The name will be implemented in the coming days and weeks. The stock ticker symbol will change from “THR” to “OXUR,” according to a company press release.
“The new name, Oxurion, is designed to better reflect our ambition to deliver best-in-class therapies for back of the eye disorders. The renaming comes at a moment when we have delivered important clinical milestones and are accelerating the development of our unique pipeline of disease-modifying compounds for diabetic eye disease. Moreover, we are also expanding our drug development efforts into new back of the eye indications where there is clear need for improved therapeutic options,” Patrik De Haes, MD, CEO of ThromboGenics, said in the release.
The company’s website will be www.oxurion.com.